2. Search Result
Search Result
Results for "

hba1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

1

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus [1] .
    Insulin icodec
  • HY-B0920
    Tolazamide
    2 Publications Verification

    U-17835

    		 Potassium Channel Metabolic Disease Endocrinology
    Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
    Tolazamide
  • HY-120565
    WB403

    		G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes [1].
    WB403
  • HY-RS06024
    HBA1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HBA1 Human Pre-designed siRNA Set A contains three designed siRNAs for HBA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HBA1 Human Pre-designed siRNA Set A
    HBA1 Human Pre-designed siRNA Set A
  • HY-178780
    MKP10241

    		GPR119 Metabolic Disease
    MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH [1].
    MKP10241
  • HY-117075
    BI-44847

    		SGLT Metabolic Disease
    BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM) [1].
    BI-44847
  • HY-W751932
    Carboxy-EG6-undecanethiol

    		Biochemical Assay Reagents Others
    Carboxy-EG6-undecanethiol is an alkanethiol that suitable for self-assembly a gold thin-film substrate. Carboxy-EG6-undecanethiol can selectively capture HbA1c in sample by covalent coupling of 3-aminophenyl boronic acid (3-APBA) [1].
    Carboxy-EG6-undecanethiol
  • HY-B0920R
    Tolazamide (Standard)

    U-17835 (Standard)

    		 Reference Standards Potassium Channel Metabolic Disease Endocrinology
    Tolazamide (U-17835) (Standard) is the analytical standard of Tolazamide. This product is intended for research and analytical applications. Tolazamide is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
    Tolazamide (Standard)
  • HY-P992007
    PF-06293620

    RN909

    		 GCGR Metabolic Disease
    PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus [1].
    PF-06293620
  • HY-17604
    Bexagliflozin
    1 Publications Verification

    EGT1442; EGT0001442; THR-1442

    		 SGLT Cardiovascular Disease Metabolic Disease
    Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke [1].
    Bexagliflozin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: